Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry

Therapeutic Drug Monitoring

Volumn 37, Issue 2, 2015, Pages 141-146

  Rochat, Bertrand ^a,b   Dahmane, Elyes ^a,b   Zaman, Kalil ^a   Csajka, Chantal ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; TAMOXIFEN; DRUG;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TRANSFORMATION; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRIPLE QUADRUPOLE MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PHARMACOKINETICS; PROCEDURES;

HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TAMOXIFEN;

EID: 84925843301     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000129     Document Type: Article

References (19)

1. Dahmane E, Boccard J, Csajka C, et al. Quantitative monitoring of tamoxifen in human plasma extended to forty metabolites using liquid-chromatography-high resolution-mass spectrometry: new investigation capabilities for clinical pharmacology. Anal Bioanal Chem. 2014;406:2627-2640.
2. Rochat B. Quantitative/qualitative analysis using LC-HRMS: the fundamental step forward for clinical laboratories and clinical practice. Bioanalysis. 2012;4:1709-1711.
3. Kaufmann A, Butcher P, Maden K, et al. Comprehensive comparison of liquid chromatography selectivity as provided by two types of liquid chromatography detectors (high resolution mass spectrometry and tandem mass spectrometry) "where is the crossover point?" Anal Chim Acta. 2010;673:60-72.
4. Ramanathan R, Korfmacher W. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis. 2012;4:467-469.
5. Henry H, Sobhi HR, Scheibner O, et al. Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun Mass Spectrom. 2012;26:499-509.
6. Rochat B, Kottelat E, McMullen J. The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantification. Bioanalysis. 2012;4:2939-2958.
7. Rochat B, Fayet F, Widmer N, et al. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J Mass Spectrom. 2008;43:736-752.
8. Williams D. Monitoring medicines use: the role of the clinical pharmacologist. Br J Clin Pharmacol. 2012;74:685-690.
9. Food and Drug Administration. Available at: http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm. Accessed June 8, 2014.
10. Gautier S, Bachelet H, Bordet R, et al. The cost of adverse drug reactions. Expert Opin Pharmacother. 2003;4:319-326.
11. Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet. 2011;26:3-14.
12. Egan LJ. Mechanisms of drug toxicity or intolerance. Dig Dis. 2011;29:172-176.
13. Food and Drug Administration. Guidance for Industry: Safety Testing of Drug Metabolites. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatory Information/Guidances/ucm079266.pdf Accessed June 8, 2014.
14. Food and Drug Administration. Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm073246.pdf. Accessed June 8, 2014.
15. Gao H, Obach RS. Addressing MIST (Metabolites in Safety Testing): bioanalytical approaches to address metabolite exposures in humans and animals. Curr Drug Metab. 2011; 12:578-586.
16. World Health Organization. The Importance of Pharmacovigilance. Available at: http://apps.who.int/medicinedocs/pdf/s4893e/s4893e. pdf. Accessed June 8, 2014.
17. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/GuidanceCompliance RegulatoryInformation/Surveillance/Adverse DrugEffects/default.htm
18. European Medicines Agencies. European Medicines Agency boosts EU transparency with online publication of suspected side effect reports. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2012/05/WC500127957.pdf. Accessed June 8, 2014.
19. Kalgutkar AS, Soglia JR. Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol. 2005;1:91-142.